Hi Davy
The following statement is interesting, and certainly NOT a 'throw-away line ...
The OASIS trial is a first-in-class clinical trial combining a CD19-expressingoncolytic virus, which flags solid tumours for attack by CD19-targeting therapeuticssuch as Amgen’s Blincyto®, Gilead’s Yescarta® and Imugene’s own allogeneic CAR T,azer-cel
If we were in any doubt where they were going to take onCARlytics, then here it is in black and white.
Discussions must be well advanced with Gilead already, or they just wouldn't have thrown this out there.
We already knew that onCARlytics would be in combo with azer-cel, as soon as it has an FDA approval. I suspect that no time will be wasted in these (azer-cel) trials now. Any sign of a positive signal with Blincyto, will not only have the other 2 mentioned above in combo ... but other suitors will come knocking.
Yes, definitely ... OASIS potentially represents a paradigm shift in solid tumour treatment.
Things are moving smoothly IMO.
Just the opinion of one poster
Hi DavyThe following statement is interesting, and certainly NOT...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
-0.001(0.70%) |
Mkt cap ! $512.3M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.4¢ | 7.0¢ | $1.175M | 16.58M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5824 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 168232 | 1 |
View Market Depth
| Last trade - 15.59pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
-0.001 ( 1.25 %) |
||||
| Open | High | Low | Volume | ||
| 7.2¢ | 7.3¢ | 7.0¢ | 6411396 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| IMU (ASX) Chart |